Headlines about Nabriva Therapeutics AG (NASDAQ:NBRV) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nabriva Therapeutics AG earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.3995661620601 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of equities analysts recently issued reports on NBRV shares. Cantor Fitzgerald started coverage on Nabriva Therapeutics AG in a report on Thursday, June 22nd. They issued a “buy” rating and a $16.00 target price on the stock. ValuEngine upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. Zacks Investment Research cut Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Finally, SunTrust Banks, Inc. started coverage on Nabriva Therapeutics AG in a report on Friday, August 25th. They issued a “buy” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Nabriva Therapeutics AG currently has an average rating of “Buy” and a consensus price target of $18.78.

Nabriva Therapeutics AG (NBRV) opened at 6.64 on Friday. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $14.10. The company’s market capitalization is $178.20 million. The company has a 50 day moving average price of $8.16 and a 200-day moving average price of $9.64.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. Analysts expect that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.

In other news, major shareholder Hbm Healthcare Investments (Ca sold 19,803 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $10.50, for a total value of $207,931.50. Following the sale, the insider now directly owns 2,373,387 shares of the company’s stock, valued at $24,920,563.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was bought at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 57,219 shares of company stock worth $535,919 and sold 81,585 shares worth $785,050. 2.75% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Nabriva Therapeutics AG (NBRV) Share Price” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/20/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-nabriva-therapeutics-ag-nbrv-share-price.html.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.